Mylan inks deal with Biocon for insulin analogs but preps for more in India?
This article was originally published in Scrip
Executive Summary
Mylan, the world's third largest generics and specialty pharmaceutical company, is upping its engagement with Indian firms. It has entered into a collaboration with Biocon, India's largest biotechnology company by revenue, to develop and commercialize generic versions of three insulin analog products, amid talk that it may also be keen to snap up a formulations plant.